Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2010-01-27
2011-12-27
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S211100
Reexamination Certificate
active
08084037
ABSTRACT:
The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.
REFERENCES:
patent: 5166057 (1992-11-01), Palese et al.
patent: 5854037 (1998-12-01), Palese et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6136585 (2000-10-01), Ball et al.
patent: 6248578 (2001-06-01), Banerjee et al.
patent: 6764685 (2004-07-01), Haller et al.
patent: 6811784 (2004-11-01), Haller et al.
patent: 7208161 (2007-04-01), Murphy et al.
patent: 7238481 (2007-07-01), Haller et al.
patent: 7341729 (2008-03-01), Haller et al.
patent: 2008/0096263 (2008-04-01), Haller et al.
patent: 0 702 085 (2010-01-01), None
patent: 58-116422 (1983-09-01), None
patent: WO 89/10405 (1989-11-01), None
patent: WO 93/14207 (1993-07-01), None
patent: WO 96/34625 (1996-11-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 97/34008 (1997-09-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/13501 (1998-04-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/02657 (1999-01-01), None
patent: WO 99/15672 (1999-04-01), None
patent: WO 01/03744 (2001-01-01), None
patent: WO 01/04320 (2001-01-01), None
patent: WO 01/42445 (2001-06-01), None
patent: WO 01/70032 (2001-09-01), None
patent: WO 02/02605 (2002-01-01), None
Bailly, Jane E. et al., 2000, “A Recombinant Human Parainfluenza Virus Type 3 (PIV3) in Which the Nucleocapsid N Protein Has Been Replaced by That of Bovine PIV3 Is Attenuated in Primates”, Journal of Virology, 74(7):3188-3195.
Bailly, Jane E. et al., 2000, “Sequence Determination and Molecular Analysis of Two Strains of Bovine Parainfluenza Virus Type 3 That Are Attenuated for Primates”, Virus Genes, 20(2):173-182.
Breker-Klassen, Michelle M. et al., 1996, “Comparisons of the F and HN gene sequences of different strains of bovine parainfluenza virus type 3: relationship to phenotype and pathogenicity”, Can. J. Vet. Res. 60(3):228-236.
Coelingh, Kathleen L. van wyke et al., 1988, “Attenuation of Bovine Parainfluenza Virus Type 3 in Nonhuman Primates and Its Ability to Confer Immunity to Human Parainfluenza Virus Type 3 Challenge”, The Journal of Infectious Diseases, 157(4):655-662.
Collins, Peter L. et al., 1991, “Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene”, Proc. Natl. Acad. Sci. USA, 88:9663-9667.
Collins, Peter L. et al., 1995, “Production of infectious human respiratory syncytial virus from cloned cDNa confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development”, Proc. Natl. Acad. Sci. USA, 92:11563-11567.
Dimock, Kenneth et al., 1993, “Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3”, J. Virol. 67:2772-8.
Durbin, Anna P. et al., 1997, “Recovery of infectious human parainfluenza virus type 3 from cDNA”, Virology, 235:323-332.
Haller, Aurelia A. et al., 2000, “Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector”, J. Virol. 74(24):11626-11635.
Karron, Ruth A. et al., 1995, “A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children”, J. Infect. Dis. 171(5):1107-1114.
Karron, Ruth A. et al., 1996, “Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two-to six-month-old infants”, Pediatr Infect Dis. J. 15(8):650-654.
Kato, Atsushi et al., 1996, “Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense”, Genes to Cells, 1:569-579.
Klippmark, Ewa et al., 1990, “Antigenic variation of human and bovine parainfluenza virus type 3 strains”, J. Gen. Virol. 71: 1577-80.
Krystal, Mark et al., 1986, “Expression of the three influenza virus polymerase proteins in a single cell allows growth complementation of viral mutants”, Proc. Natl. Acad. Sci. USA, 83:2709-2713.
Luytjes, Willem et al., 1989, “Amplification, Expression, and Packaging of a Foreign Gene by Influenza Virus”, Cell, 59:1107-1113.
MedImmune's Press Release, Dated Jul. 3, 2007, “Medlmmune Begins Dosing Children Six Months to 24 Months of Age in Phase 1 Study of Vaccine to Help Prevent Two of the Most Common Viral Causes of Childhood Respiratory Illness”.
Neumann, Gabriele et al., 2002, “A decade after the generation of a negative-sense RNA virus from cloned cDNA- what have we learned?”, Journal of General Virology, 83:2635-2662.
Palese, Peter et al., 1996, “Negative-strand RNA viruses: genetic engineering and applications”, Proc. Natl. Acad. Sci. U S A, 93:11354-11358.
Park, Kyeong H. et al., 1991, “Rescue of a foreign gene by Sendai virus”, Proc. Natl. Acad. Sci. USA, 88:5537-5541.
Partial European Search Report mailed Feb. 8, 2011 for EP Application No. 10185932.0.
Schmidt, Alexander C. et al., 2000, “Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates”, J. Virol. 74(19):8922-8929.
Schnell, Matthias J. et al., 1994, “Infectious rabies viruses from cloned cDNA”, The EMBO Journal, 13(18):4195-4203.
Shibuta, Hiroshi et al. 1979, “Characterization of bovine parainfluenza virus type 3”, Microbiol. Immunol. 23(7):617-628.
Skiadopoulos, Mario H. et al., 1998, “Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes”, J. Virol. 72(3):1762-1768.
Skiadopoulos, Mario H. et al., 2001, “A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys”, J. Virol. 75(21):10498-504.
Tao, Tao et al., 1998, “Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1”, J. Virol. 72(4):2955-2961.
Tao, T. et al., 1999, “A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge”, Vaccine, 17:1100-1108.
Schmidt, Alexander C. et al., 2001, “Recombinant Bovine/Human Parainfluenza Virus Type 3 (B/HPIV3) Expressing the Respiratory Syncytial Virus (RSV) G and F Proteins Can Be Used to Achieve Simultaneous Mucosal Immunization against RSV and HPIV3”, Journal of Virology, 75(10):4594-4603.
Schmidt, Alexander C. et al., 2002, “Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector Backbone”, Journal of Virology, 76(3): 1089-1099.
Stope, Matthias B. et al., 2001, “Chimeric Bovine Respiratory Syncytial Virus with Attachment and Fusion Glycoproteins Replaced by Bovine Parainfluenza Virus Type
Coelingh Kathleen
Haller Aurelia
MedImmune LLC
Salimi Ali R.
LandOfFree
Recombinant parainfluenza virus expression systems and vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant parainfluenza virus expression systems and vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant parainfluenza virus expression systems and vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4256978